1. Scrip
  2. >>Conferences
  3. >>ASCO

ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

KEYNOTE-355 Mixed On PFS; Still Waiting On OS

 
• By Eleanor Malone

Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.  

Dividing breast cancer cell

New data to be presented by Merck & Co. Inc. at the upcoming American Society of Clinical Oncology virtual meeting represent a step forward in its bid to challenge Roche’s stronghold in immunotherapy for triple-negative breast cancer. However, Roche need not start quaking in its boots just yet.

Merck is set to present updated results on its PD-1 inhibitor Keytruda (pembrolizumab) in first-line treatment of triple-negative breast cancer (TNBC), an indication for which Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) became the first

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

TIL The CARs Come Home: How Cell Therapy’s Solid Tumor Future Is Shaping Up

 
• By Alaric DeArment

Iovance’s Amtagvi won FDA accelerated approval in February, and Adaptimmune’s afami-cel may not be far behind, but cell therapies for solid tumors come with some extra challenges.

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

ASCO 2024 Wrap-Up Podcast

 
• By Alaric DeArment

Scrip reporter Alaric DeArment is joined by the Datamonitor Healthcare oncology analysts to review key highlights from the recent American Society of Clinical Oncology annual meeting.   

More from Conferences

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

 
• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By Kevin Grogan

The UK giant is forecasting peak sales of $5bn plus

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.